Gladys Rodriguez,MD, FASCO

I am honor to join @NarjustDumaMD and @ASCO @ConquerCancerFd to fund a YIA for Latinas in oncology conquer.org/WWCCGIFT @SandraSwainMD @EdithPerezMD @ASCOPres Please help us reach the goal! @HemOncWomenDocs

@Latinamd @DrRobWinn @TempleHealth Live thru it!

Fighting cancer is hard enough—patients shouldn't have to fight for coverage, too. ASCO’s new position statement on H.R. 1 aims to protect the #Medicaid safety net and ensure paperwork never stands between a patient and life-saving care: bit.ly/3MxU9n5 #ASCOAdvocacy

@barbarasegarra I’m looking forward to be back participate as faculty, and meet amazing patient advocates @barbarasegarra

Proud and happy we will have the 2nd Latino Cancer Patient Advocate Training Program. Grateful to the sponsors that with their support make this happen. We have 16 new participants from 9 different types of cancer experiences & 7 different States and PR. Dreams do come true🤗

“Multidisciplinary care for a patient who's diagnosed with cancer while pregnant is essential.” In this “Science in Seconds,” @AnnPartridgeMD & Dr. Alison Loren discuss our first guideline on cancer during pregnancy. Read the guideline in @JCO_ASCO: brnw.ch/21wYhKK

Calling all early-career oncologists in #LMICs! The @ConquerCancerFd Long-term International Fellowship (LIFe) is OPEN. Get mentor-led training in the U.S., Canada, or Europe to advance cancer care in your community. Apply by 1/29/2026: brnw.ch/21wYfku #GlobalOncology

Dr @elmayermd with a @DrHBurstein slide on all our post CDK4/6 inhibitor trials #SABCS25

@NarjustFlorezMD @YoungLungCancer @DanaFarberNews @DFEGFRcenter @Florez_Lab @GMA @OncoAlert @AnaVManana @ASridharMD @Latinamd @EGFRResisters @ALKPositiveinc @Yvonne_Diaz_ @GlopesMd @OncBrothers @oncodaily @OncogeneCancer Congrats!! Love to see your accomplishments💖

Tune in today for our segment on Good Morning America about Young Lung Cancer - 8:30 am EST. @YoungLungCancer @DanaFarberNews @DFEGFRcenter @Florez_Lab @GMA @OncoAlert

🚨 St Gallen 2025: Evidence-backed upgrades in early breast cancer A consensus now aligned with KEYNOTE-522, TAILORx, SOUND, INSEMA, KATHERINE and OlympiA. 1) Genetics & Prevention 🧬 BRCA1/2, PALB2 → strong support for contralateral risk-reducing surgery. 📌 Evidence: OlympiA, TBCRC 048. 2) DCIS 🟦 BCS + RT remains standard; endocrine therapy for ER+. ⛔ Active monitoring not yet routine. 📌 Evidence: COMET. 3) Breast Surgery 🔪 BCS preferred, even for selected multifocal cases. 📌 Evidence: NSABP B-06, ACOSOG Z11102. 4) Axilla De-escalation 🟩 SLNB omission allowed in postmenopausal, ER+, T1, USG-negative axilla. 🟥 Not allowed in HER2+, TNBC, lobular, premenopausal. 📌 Evidence: SOUND, INSEMA. After NAC → TAD validated (ACOSOG Z1071, SENTINA). 5) Radiation Therapy ⚡ Hypo and ultra-hypo preferred (FAST-Forward). 🤔 RT omission in older low-risk women still debated (PRIME II, CALGB 9343, IDEA, EUROPA). ♻ Re-irradiation allowed if recurrence ≥5 yrs. 6) Triple-Negative (TNBC) 🔥 Standard: NAC chemo + immunotherapy. Continue pembro regardless of pCR. 💊 Residual disease → pembro + capecitabine; or olaparib if BRCA+. 📌 Evidence: KEYNOTE-522, GeparNuevo, IMpassion031, CREATE-X. 7) HER2-Positive 👑 Preferred NAC → TCbHP; THP acceptable in moderate risk. 🔁 Residual disease → T-DM1. 📌 Evidence: TRAIN-2, KRISTINE, KATHERINE, APHINITY. 8) ER-Positive / HER2-Negative 📉 Chemo only when absolute distant risk reduction ≥3–5 percent. 🧬 Genomic signatures guide decisions. 🌀 High-risk → CDK4/6 inhibitor (abemaciclib). 📌 Evidence: TAILORx, RxPONDER, MINDACT, monarchE, SOFT/TEXT. 9) Local Recurrence 🔁 Re-excision + re-irradiation feasible. 🎯 Repeat SLNB supported. 📌 Evidence: RTOG 1014. 10) Oligometastatic 🎯 Curative-intent therapy only for ≤1–2 sites + strong response to induction therapy. 📌 Evidence: SABR-COMET signal + breast-specific cohorts. Takeaway St Gallen 2025 = precision escalation (TNBC, HER2+, high-risk ER+) + safe de-escalation (SLNB omission, hypo-RT) backed by the strongest trials to date. #OncoTwitter #MedTwitter #BreastCancer @OncoAlert @myesmo @esmo_open @asco

The first new adjuvant endocrine treatment to improve outcomes for breast cancer in decades. Tucatinib improving outcomes in the first line HER2+ setting. First phase 3 data with SG in chemo-naive pts with HR+ MBC. And so much more. See you in a few days in San Antonio! #SABCS25

Excited to make it to the cover of @NatureRevCancer (December Issue) with our review on the Molecular and Immunological drivers of ADCs! 🔦 Time to shed some light on this complex chemo delivery mechanism 🎯 Read it here: nature.com/articles/s4156…

@DrSGraff @SABCSSanAntonio @AMJohnston1315 Hear Her, she speaks for all pts with cancer.

Abigail’s voice is so strong and true— But also, this is truly reflective of the wishes of our patients at large. Take time to listen. #SABCS25 @SABCSSanAntonio @AMJohnston1315

Hear her! Great campaign about awareness of lung cancer in women. Gracias ⁦@NarjustFlorezMD⁩ for the beutiful pin

#ASCO25 #MetastaticBreastCancer Poster Session: Assessing the impact of #ScalpCooling in patients receiving #TrastuzumabDeruxtecan for metastatic #BreastCancer. @esalehiDNP Abs 1095 | Poster Bd 74 | Jun 2, 9-12 PM CDT | Hall A

#ASCO25 Metastatic #BreastCancer Poster Session: Quantitative pre-treatment assessment of trastuzumab deruxtecan (#TDXd) antibody target (HER2) and payload target (topoisomerase 1, Topo1) to predict outcomes in #MetastaticBreastCancer (#MBC). @PTarantinoMD Abstract 1032 | Poster Bd 11 | Jun 2, 9-12 PM CDT | Hall A

As anticipated, SERENA-6 creates a lot of questions. PFS-2 is immature and crossover was not allowed; given PFS on postMonarch & EMBER-3 combo, it is unclear to me that early switch based on molecular disease is practice changing. #ASCO25

#ASCO25 Poster Session on #MBC 👉 #DATOBase: A phase II study of DATOpotamab deruxtecan for patients with #BreastCancerBrainMetastases or #Leptomeningeal disease. Abs TPS1134 | Post Bd 106a| Jun 2 9-12 PM CDT | Hall A @PTarantinoMD @drsarahsam @stolaney1 @nlinmd #BrainMetastases #LMD #LeptomeningealDisease

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

🔔Make sure to check our study!! @ASCO #ASCO25 ⭐️#HighFiber (HF) #diet to modulate microbiome and outcomes in #immunotherapy in #Melanoma ✅ORR: ⬆️HF 77% Cntrl 29% ✅No significant GI related or Immune related AEs with HF diet ✅Cutaneous adverse events⬇️ w HF ✅ impressive EFS w HF 🐁 Supportive preclinical data 👏Wonderful presentation by ⭐️ @yqiuMDPhD! Great to be a part of this study under mentorship of #DrJenniferMcQuade @JenWargoMD #DrCarrieMacDougall @MDAndersonNews @montypal @OncoAlert @IMG_Oncologists @ASCOTECAG @HemOncFellows @HTawbi_MD @ppisters @lungoncdoc @PavlosMsaouel @OncHahn #MedEd

Wow, right? 7:30 Monday at #ASCO25. Agree! No doubt #DB09 will be practice changing. The question is, how will we handle maintenance?

All of our @Florez_Lab members are BUSY at work here @ASCO! Day 4 is absolutely packed. Starting off the morning with @AnaVManana #FASCO. She has not 1, not 2, but 3 events today! If you haven't been able to catch her, you can come support her at the following events: 1. 💬 Moderator: “Finding Funding” Join this empowering session for women in oncology📍 Room S502 | 11:00–11:45 AM 2. Panelist: “Finding Your First Job” 📍 Hall C | 1:00–1:45 PM Career insights for early-career oncologists—don’t miss it! 3. Poster session: "Evaluation of NCI Designated Cancer Centers medical student education and training initiatives" 📍 Hall A | 1:30–4:30 PM